metreleptin: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
metreleptin: clinical details
Prescribing considerations
- Confirm the lipodystrophy subtype and licensed eligibility; evidence does not support HIV-related lipodystrophy.
- Review diabetes and lipid-lowering treatment because metabolic improvement may alter requirements.
- Avoid abrupt withdrawal in patients at risk of hypertriglyceridaemia-associated pancreatitis; plan discontinuation with triglyceride monitoring and dietary support.
- Consider individual benefit and risk in previous lymphoma, haematological abnormalities, autoimmune disease, pancreatitis, serious infection, renal impairment or hepatic impairment.
- Review preparation and self-injection technique periodically to reduce medication errors and intramuscular injection.
Contraindications and cautions
- Hypersensitivity to metreleptin or any excipient.
Monitoring
- Weight, appetite and excessive weight loss, particularly in children
- Glucose control and hypoglycaemia when diabetes medicines are used
- HbA1c, triglycerides and other relevant metabolic outcomes
- Signs of pancreatitis, serious infection, hypersensitivity, lymphoma or autoimmune flare
- Clinical response and correct reconstitution and injection technique
- Effect or concentration of narrow-therapeutic-index CYP substrates when metreleptin is started or stopped
Clinical pharmacology
Metreleptin is recombinant methionyl-human leptin. It activates the human leptin receptor through JAK–STAT signalling. Pharmacokinetic data in lipodystrophy are limited; non-clinical evidence indicates renal clearance is the main elimination route, with no formal metabolism studies available.
Formulation and product differences
- The selected product is a 3 mg vial containing white powder for subcutaneous injection after reconstitution. The resulting solution is for immediate, single use and must not be stored.
metreleptin preparations and strengths
Injection
Route: Parenteral
Strengths: 3 mg, 5.8 mg, 11.3 mg
metreleptin interactions
Human interaction studies are limited. Important potential interactions include:
Insulin and insulin secretagogues
Improved insulin sensitivity can increase hypoglycaemia risk, requiring close glucose monitoring and review of diabetes treatment.
Hormonal contraceptives
Contraceptive effectiveness may be reduced; an additional non-hormonal method should be considered.
Warfarin and similar narrow-therapeutic-index medicines
Metreleptin may alter CYP-mediated exposure, so treatment effect should be monitored when metreleptin is started or stopped.
Sources
These sources were used to prepare and review this medicine page.
iatroX CPD
Keep a note for CPD
Save a private reflection with this source attached. Your first is free.
Record learning (opens in a new tab)Prepared and reviewed by the iatroX editorial team.